pancreatitis from glp 1 GLP-1 medications for type 2 diabetes and obesity may lower risk of acute Pancreatitis Recurrence Risk Lower With

4-6% placebo Diarrhea: 12-17% Vomiting: 5-10% Constipation: 6-11% Decreased appetite: 5-11% GI events are predominantly mild-moderate and occur mainly during dose escalation (first 4-8 weeks), with significant attenuation over time Serious adverse events of interest : Pancreatitis : Adjudicated pancreatitis events occurred at rates of approximately 0.1-0.2% across the SURPASS program, comparable to rates seen with GLP-1 agonists

Enter Andel

Emerging trends in pain modulation by metabotropic glutamate receptors

Pain Management and Inflammation Control Manual therapy, dry needling, and targeted mobility drills help reduce pain and calm down the joint

Fast Australia-wide dispatch

Reference Bowers, C